EU CHMP recommends Roche’s Perjeta for pre-surgery use in breast cancer
The European Union (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval Roche's Perjeta along with Herceptin and chemotherapy for neoadjuvant treatment of adult patients with HER2-positive early breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 28, 2015 Category: Pharmaceuticals Source Type: news

Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model
Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer. In order to improve the efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules, and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, i.e., intramuscular or intradermal application with or without coexpression of adjuvants. Protection from tumor growth in tumor chal...
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news

Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
Aptamers are an emerging class of molecules in cancer therapy. They can be easily synthesized and are considered cost-effective drug candidates. In this book chapter we describe the selection and characterization of DNA aptamers specific to the human epidermal growth factor receptor 2 (ERBB2/HER2), an oncogenic tyrosine kinase. First, a DNA aptamer library is applied and ERBB2-specific aptamers are selected using SELEX. Binders are subcloned into a pGEM-T vector, sequenced, and characterized using biochemical and cell biological techniques. By multimerizing the selected ERBB2 aptamers, it might be possible to significantly...
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news

EU Recommends Approval of Neoadjuvant Pertuzumab RegimenEU Recommends Approval of Neoadjuvant Pertuzumab Regimen
CHMP has cleared the way for approval of pertuzumab combined with traztuzumab and other agents in the neoadjuvant setting for women with early HER2-positive breast cancer. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 26, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 26, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 26, 2015 Category: Pharmaceuticals Source Type: news

Neratinib Lowers Recurrence in High-Risk HER2+ Breast CancerNeratinib Lowers Recurrence in High-Risk HER2+ Breast Cancer
Dr Lidia Schapira gives the take-home messages from breast cancer sessions of ASCO 2015, including top studies in HER2+ and HR+ disease, and new findings for managing side effects of treatment. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

UCLA receives $1 million from Revlon to fund breast cancer research
UCLA has received a $1 million donation from Revlon that will support the Revlon/UCLA Women’s Cancer Research Program and further the company’s long-standing commitment to eradicating women’s cancers. The gift was announced by Revlon CEO Lorenzo Delpani, chairman Ronald O. Perelman and global brand ambassador Halle Berry at an event honoring Dr. Dennis Slamon, a member of the UCLA Jonsson Comprehensive Cancer Center and director of the Revlon/UCLA Breast Cancer Center Director for his outstanding achievements in cancer research. “We have made tremendous advancements in the field of breast cancer tre...
Source: UCLA Newsroom: Health Sciences - June 8, 2015 Category: Universities & Medical Training Source Type: news

HER2 Bladder Cancer: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, we hear from Dr. John Cheville about a study which looked as some similarities between some breast and bladder cancers. To listen, click the link below. HER2 Bladder Cancer (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 8, 2015 Category: Databases & Libraries Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - June 1, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2015 Category: Pharmaceuticals Source Type: news

Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 30, 2015 Category: Pharmaceuticals Source Type: news

ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About...
At ASCO 2015, University of Colorado Cancer Center reports promising clinical trial results of ONT-380 against HER2+ breast cancer(PRWeb May 30, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12756741.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 30, 2015 Category: Pharmaceuticals Source Type: news

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
Promising clinical trial results show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 29, 2015 Category: Science Source Type: news

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
(University of Colorado Denver) Promising clinical trial results presented at the American Society for Clinical Oncology Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2015 Category: Biology Source Type: news

[Research Article] HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive
Exploiting the dependence of some cancer cells on an ER stress response pathway may overcome resistance to some chemotherapeutics. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 26, 2015 Category: Science Authors: Navneet Singh, Rashika Joshi, Kakajan Komurov Source Type: news

SHAVE a Big Plus in Breast CancerSHAVE a Big Plus in Breast Cancer
Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 22, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

[Focus] A new strategy to ERADicate HER2-positive breast tumors?
Targeting a proteotoxic stress response pathway may improve therapeutic outcomes for HER2-positive breast cancer patients. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 22, 2015 Category: Science Authors: Sanjeevani Arora and Erica A. Golemis Source Type: news

Risk of Subsequent Breast Cancer in Human EGFR 2-Positive DCISRisk of Subsequent Breast Cancer in Human EGFR 2-Positive DCIS
What's the prognostic role of HER2 overexpression in patients with ductal carcinoma in situ? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Is Genetic Testing for Breast Cancer Right for You?
Susan K. Boolbol, MD Chief, Division of Breast Surgery Mount Sinai Beth Israel For most women, the average risk of developing breast cancer is about 12 percent. However, if you have a mutation on either of the two most common genes associated with breast cancer -- BRCA1 and BRCA2 -- that risk can jump as high as 80 percent. While it's natural to wonder if you might have inherited an abnormal BRCA gene from one of your parents, it's also important to remember that only about 5-10 percent of breast cancers are due to hereditary mutations; the overwhelming majority of women with breast cancer have no family history of the di...
Source: Healthy Living - The Huffington Post - May 6, 2015 Category: Consumer Health News Source Type: news

Breast cancer vaccines may work better with silicon microparticles
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists. Model studies showed that microparticles loaded with an antigen, HER2, not only protected the antigen from premature destruction, but also stimulated the immune system to recognize and relentlessly attack cancer cells overexpressing the HER2 antigen. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2015 Category: Science Source Type: news

HR+/HER2- Advanced Breast Cancer Pretreated With Non-Steroid AIsHR+/HER2- Advanced Breast Cancer Pretreated With Non-Steroid AIs
Compare results of trials on endocrine or targeted treatment in HR+/HER2- mBC patients who progressed after a prior NSAI therapy. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HER2 Dependency in Lung CancersHER2 Dependency in Lung Cancers
What have we learned about treating HER2-mutant lung cancers? Dr Mark Kris explores this new topic in the field of thoracic oncology. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Master switch for cancer-causing HER2 protein identified
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2015 Category: Science Source Type: news

Mayo Clinic-led research team identifies master switch for cancer-causing HER2 protein
(Mayo Clinic) Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2015 Category: Cancer & Oncology Source Type: news

Mayo Clinic-led Team Identifies Master Switch for Cancer-Causing HER2 Protein
ROCHESTER, Minn. — Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. A team of researchers [...] (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - April 27, 2015 Category: Hospital Management Source Type: news

Breakthrough provides new hope for more effective treatments of HER2+ breast cancer
(Case Western Reserve University) Ahmad M. Khalil, Ph.D., and his team identified the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. Their findings appear this month in Breast Cancer Research and Treatment about 38 genes and molecules that most likely trigger HER2+ cancer cells to spread. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2015 Category: Global & Universal Source Type: news

New signaling pathway discovered in HER2-positive breast cancer, and 2 powerful drug targets
(Cold Spring Harbor Laboratory) A team at CSHL has published results of experiments that lay bare a previously unknown pathway activated in a highly lethal form of breast cancer. The pathway, they discovered, contains at least two potentially powerful drug targets, according to the team leader. The breast cancer type is called HER2-positive, and affects about one cancer patient in four. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2015 Category: Cancer & Oncology Source Type: news

Researchers find new approach to treat drug-resistant HER2-positive breast cancer
(University of North Carolina Health Care) Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy. Using human cell lines of the HER2-positive breast cancer subtype, researchers from the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center have detailed the surprising ways in which resistance manifests and how to defeat it before it happens. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2015 Category: Cancer & Oncology Source Type: news

HER2-positive breast cancer: What is it?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - March 25, 2015 Category: Consumer Health News Source Type: news

HER2 Positivity in Gastroesophageal AdenocarcinomaHER2 Positivity in Gastroesophageal Adenocarcinoma
This report validates the currently used standardized HER2 scoring system for establishing HER2 status in gastroesophageal adenocarcinomas. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 24, 2015 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Tykerb Still Falls Short in HER2-Positive Breast Ca (CME/CE)
(MedPage Today) -- Lapatinib plus taxane leads to shorter progression-free survival, more toxicity. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 18, 2015 Category: Primary Care Source Type: news

UK Recommendations for HER2 Assessment in Breast CancerUK Recommendations for HER2 Assessment in Breast Cancer
This paper provides an update of the guidelines for HER2 testing in the UK, covering methodology, testing algorithms, interpretation of results and the potential need for retesting. Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2015 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

HER2-Positive Metastatic Breast Cancer: New Standard of CareHER2-Positive Metastatic Breast Cancer: New Standard of Care
Combining two targeted agents, trastuzumab and pertuzumab, with docetaxel resulted in unprecedented survival in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA approves new drug to treat estrogen-receptor–positive breast cancer
The U.S. Food and Drug Administration today approved a new drug to treat patients with advanced breast cancer, signaling a new strategy for arresting tumor growth and extending the time before cancer worsens in women with metastatic disease. The drug, Ibrance (palbociclib), was studied in 165 post-menopausal women with advanced estrogen–receptor positive (ER+) and HER2–negative (HER2-) breast cancer who had received no prior systemic therapy for their metastatic disease. In 2013, after patients in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted the drug “breakthroug...
Source: UCLA Newsroom: Health Sciences - February 3, 2015 Category: Universities & Medical Training Source Type: news

Dartmouth researchers discover new mechanism of acquired resistance to breast cancer drugs
(The Geisel School of Medicine at Dartmouth) In the search for new approaches to treat ERBB2 -- also known as HER2 -- positive breast cancers that have become drug-resistant, Dartmouth investigator Manabu Kurokawa, Ph.D., led a team in discovery of a novel cancer resistance mechanism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2015 Category: Global & Universal Source Type: news

Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer
At 18 months median follow up of a phase 1 clinical trial, one patient's cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 26, 2015 Category: Science Source Type: news

Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer
(University of Colorado Denver) At 18 months median follow up, one patient's cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2015 Category: Global & Universal Source Type: news

Palbociclib for Breast Cancer Inches Toward FDA ApprovalPalbociclib for Breast Cancer Inches Toward FDA Approval
Palbociclib, the first CDK 4/6 inhibitor, has shown a doubling of progression-free survival in postmenopausal women with ER-positive, HER2-negative advanced-stage breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 21, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Potential Practice Change in Small HER2-+ Breast CancersPotential Practice Change in Small HER2-+ Breast Cancers
Less intensive chemotherapy combined with trastuzumab resulted in a very high rate of disease-free survival and suggests that more chemo is not needed in stage I disease treated with systemic therapy. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 7, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Combined therapy can reduce chance of recurrence in women with small, HER2+ breast tumors
(Dana-Farber Cancer Institute) Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 7, 2015 Category: Cancer & Oncology Source Type: news

Behind the Headlines Top Five of Top Fives 2014
As we move towards the end of the year, like all news sources, we fall back on that classic space filler – the list story. So without further ado, here is the official Behind the Headlines Top Five of Top Fives stories of 2014, in which we celebrate the good, highlight the bad, check out the weird and answer some of the burning questions of the year. The top five 'Good work boffins!' stories of the year We can often get bogged down in pointing out dodgy sub-group analyses, spurious extrapolations of sample sizes containing just 20 rats and a water maze, and RCTs pointing out the benefits of cherries on dementia preve...
Source: NHS News Feed - December 31, 2014 Category: Consumer Health News Tags: QA articles Medical practice Source Type: news

Neoadjuvant Therapy for HER2-Positive Breast CancerNeoadjuvant Therapy for HER2-Positive Breast Cancer
Learn more about the most effective treatment modality in the neoadjuvant setting for HER2-positive breast cancer. Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HER2+ Therapy: Getting Less Toxic All the TimeHER2+ Therapy: Getting Less Toxic All the Time
Drs Kathy Miller and Clifford Hudis discuss at SABCS 2014 recent advances in HER2+ breast cancer, focusing on the growing interest in lowering the toxicity of therapy. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Newest HER2-Targeted Therapy No Better Than Original AgentNewest HER2-Targeted Therapy No Better Than Original Agent
Top-line results from the MARIANNE trial show that the latest HER-targeted agent T-DM1 is no better than the original, trastuzumab Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ImmunoGen shares plunge premarket after failure of breast cancer trial
ImmunoGen, the maker of breast cancer drug Kadcyla, saw it's shares drop be nearly half in pre-market trading today after a late-stage trial failed to show it provided significant benefits. The Waltham biotech company's partner on the drug, Swiss drug giant Roche, reported disappointing results from a late-stage trial of the drug early this morning. The goal of the trial of 1,095 breast cancer patients was to make Kadcyla available to newly-diagnosed patients with a genetic mutation known as HER2,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 19, 2014 Category: American Health Authors: Don Seiffert Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Media News)
Source: Roche Media News - December 19, 2014 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 19, 2014 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer. (Source: Roche Media News)
Source: Roche Media News - December 19, 2014 Category: Pharmaceuticals Source Type: news

Combination drug therapy doubles positive effect of treatment for women with advanced breast cancer
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA’s Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time women with advanced breast cancer were on treatment without their cancer worsening was effectively doubled when they took the experimental drug palbociclib. An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth and prevents them from dividing. Results of the multi-year Phase 2 study showed a significant...
Source: UCLA Newsroom: Health Sciences - December 19, 2014 Category: Universities & Medical Training Source Type: news